b \x0c\x0c\x0c\x0c\x0c\x0co o o o o o o o o \x0c\x0co o o o o o o o o o \x0c\x0ca \x0cb \x0c\x0c\x0c\x0c\x0c\x0co o \x0co o \x0co \xef\x82\xa7 Support feasibility studies by affording analysis of patient populations study sites and clinical trial design Using this information clinical trial study parameters can be adjusted to maximize the trial\xe2\x80\x99s speed and cost effectiveness \xef\x82\xa7 Help establish patient cohorts and inclusion/exclusion criteria to further support clinical trial optimization For drugs that are designed to target a specific molecular pathway or gene variant omics data can provide valuable information to guide the selection of patients for all study cohorts \xef\x82\xa7 Provide insight to further classify the clinical trial population based on molecular signatures to ensure more targeted inclusion/exclusion criteria \x0cwhich will lead to smaller study populations thereby reducing costs dramatically \xef\x82\xa7 Enable adaptive clinical trials by characterizing study cohorts providing insights on drug safety and efficacy This information will determine pharmacogenomic effects to support modifications to the drug dosage patient inclusion criteria or clinical trial sample size o Patient Recruitment By some estimates patient enrollment for clinical trials is responsible for 30% of the time it takes to conduct clinical trials some sites never enroll enough patients Shivom\xe2\x80\x99s databases will have the potential to dramatically improve the recruitment process by connecting patients with trials in an anonymous fashion Pharmaceutical or CRO organizations would have access to a treasure trove of information about potential participants and the users of associated investigative sites who are likely to be motivated to join a study o Data Quality & Reproducibility Multiple reports and studies are fueling discussions about reproducibility of results especially in the biomedical sciences These discussions raise concerns about the level of trust in results in the scientific literature in public databases within organizations and from clinical studies The Shivom genomics ecosystem will be updated with new data curated for the quality of records and made compliant with local regulations for genomic data handling It is essential to maintain integrity provenance security and privacy of all sensitive information along the processes of data uploading processing analysis and sharing Systematizing this process will be essential for Shivom to dynamically accommodate and manage changes to the workflow \x0c\x0c\x0co o o o o \x0c\x0co o o o \x0co o o o o o o \x0co o o o o o o o o o o o o o o o o o o o o \x0co o o \x0co o o o o o \x0c\x0co o \x0co o \xef\x82\xa7 \xef\x82\xa7 \xef\x82\xa7 \xef\x82\xa7 \xef\x82\xa7 o \xef\x82\xa7 \x0c\xef\x82\xa7 \xef\x82\xa7 o o \x0cGlobal Alliance for Genomics & Health Pistoia Alliance CDISC EBI Ontology service \x0c\x0c\x0c\x0c\x0cc o o o \x0co \x0co o \xef\x82\xa7 \xef\x82\xa7 \x0c\xef\x82\xa7 o o \x0co o \x0cd d \x0co o o o o o o o o o o o o o o o o o o o o o o o o o o o \x0co o \x0chere \x0c\x0cAxel Schumacher PhD Co Founder & CEO Gourish Singla Co Founder & COO Sally Eaves PhD Co founder & CMO \x0cAkash Gaurav Co Founder & CTO Henry L Ines Chief Innovation Officer Natalie Pankova PhD Chief Scientific Officer Agam Kansal Marketing Lead \x0cDr Rashad Ibrahim Middle East Head Stephane Laurent Chinese Subcontinent Head Pierre Maarek Investment Lead Charles Leslie Investment Lead Kayleen Schreiber PhD Design Lead \x0cTing Peng PR Manager Azam Shaghaghi Head of Public Relations Ajit Singh Kular Head of Digital Marketing \x0cDr Jay Sanders Antanas Guoga David Orban Geoff Hancock \x0cDr William Yasnoff Dr Irshaad Ebrahim Dr Kamala K Maddali \x0c1 \x0c\x0c\x0c 